Drugs Made In America Acquisition II Corp. (DMII)
NASDAQ
Closed
Oct 6, 2026
Day's Range
10.1852 wk Range
9.86Overview - DMII - Drugs Made In America Acquisition II Corp.
Key Statistics
Valuation
Enterprise Value
649.37M
P/E (Trailing)
‪35.13‬
Price / Book
‪1.30‬
EV / EBITDA
‪-350.21‬
Profitability
Profit Margin
‪0.00%‬
Operating Margin
‪0.00%‬
Return on Assets
‪0.82%‬
Return on Equity
‪0.85%‬
Ownership
Shares Outstanding
63.70M
Float
54.00M
Short % of Shares Outstanding
‪0.21%‬
Held by Insiders
‪15.21%‬
Held by Institutions
‪72.88%‬
Price stats
50-Day Avg
‪10.14‬
200-Day Avg
‪10.04‬
Dividends
Payout Ratio
‪0.00%‬
Shariah Compliance
Report Date: Feb 16, 2025
Screened by Zoya using the AAOIFI methodology.
Market Cap - DMII - Drugs Made In America Acquisition II Corp.
Peers - DMII - Drugs Made In America Acquisition II Corp.
Peer Comparison
Compared with companies in Shell Companies listed on NASDAQ.
- DMDMIINASDAQDrugs Made In America Acquisition II Corp.649.10MMarket Cap+3.04%52-week change35.14P/E (Trailing)‪0.00%‬Profit Margin
- SLVRNASDAQSprott Silver Miners & Physical Silver ETF1.36BMarket Cap+16.25%52-week change23.47P/E (Trailing)—Profit Margin
- XRPNNASDAQArmada Acquisition Corp. II Class A Ordinary Shares790.06MMarket Cap+58.38%52-week change168.18P/E (Trailing)‪0.00%‬Profit Margin
- AVRNASDAQAnteris Technologies Ltd.748.56MMarket Cap+43.30%52-week change-3.02P/E (Trailing)‪70.25%‬Profit Margin
- CCXINASDAQChemoCentryx Inc667.84MMarket Cap+14.43%52-week change-6.34P/E (Trailing)‪99.05%‬Profit Margin
- CECEPFNASDAQCantor Equity Partners IV, Inc. Class A Ordinary Shares586.93MMarket Cap-0.78%52-week change27.76P/E (Trailing)‪0.00%‬Profit Margin
- DBCANASDAQD. Boral Acquisition I Corp. Class A Ordinary Shares557.04MMarket Cap+1.70%52-week change—P/E (Trailing)‪0.00%‬Profit Margin
Profile Summary - DMII - Drugs Made In America Acquisition II Corp.
About
Drugs Made In America Acquisition II Corp. is a blank check company focused on identifying and completing a business combination with one or more businesses in the pharmaceutical sector. As a special purpose acquisition company, it does not operate a traditional commercial business and instead serves as a vehicle for…
The information on this page is provided for general informational purposes only and is not investment advice.
Market data provided by Twelve Data. Shariah compliance data provided by Zoya. Charting by TradingView.
Last updated:
